Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$4.20
−$0.08 · -1.87%
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Latest quote
$4.20
−$0.08 · -1.87%
After-hours
$4.20
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Day range
Current $4.20
52-week range
Current $4.20
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
53
Mixed
Risk
65
High Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Day range
Current $4.20
52-week range
Current $4.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 824.5M USD | 837.6M USD | 753.2M USD | 678.4M USD | 690.6M USD |
| Cost of goods sold | 247.9M USD | 252.2M USD | 236.2M USD | 202M USD | 197.6M USD |
| Gross profit | 576.6M USD | 585.4M USD | 517M USD | 476.4M USD | 493M USD |
| Research and development | 106.8M USD | 113.4M USD | 88.7M USD | 85.4M USD | 81.9M USD |
| Selling, general, and administrative | 537.6M USD | 560M USD | 572.9M USD | 514.7M USD | 537.8M USD |
| Operating expenses | 644.4M USD | 673.4M USD | 661.6M USD | 600.1M USD | 683.5M USD |
| Interest income | 1.8M USD | 1.7M USD | 2.5M USD | 2.6M USD | 700K USD |
| Interest expense | 10.5M USD | 2.8M USD | 2.9M USD | 3.2M USD | 6.6M USD |
| Depreciation and amortization | 53.7M USD | 61.2M USD | 61.9M USD | 52.7M USD | 62.8M USD |
| Operating income | −67.8M USD | −88M USD | −144.6M USD | −123.7M USD | −190.5M USD |
| Net income | −365.9M USD | −127.3M USD | −263.3M USD | −112M USD | −27.2M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.92
6.67% downside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 1, 2009 | $1.75Monthly | — | — |
Dividend | Jun 15, 2009 | $1.75Monthly | — | — |
Ex-dividend Jul 1, 2009
$1.75
Monthly
Ex-dividend Jun 15, 2009
$1.75
Monthly
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI12.46M0.12%10.08B USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM10.25M0.01%78.56B USD0.19%$277.57-0.05%
Vanguard Morningstar Total Stock Market ETFVTI9.28M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF3.56M0.00%95.4B USD0.05%$233.13-0.15%
Fidelity Enhanced Small Cap ETFFESM3.47M0.05%6.41B USD0.28%$45.25+0.07%
iShares Biotechnology ETFIBB2.86M0.03%10.4B USD0.44%$200.48-1.41%
Schwab U.S. Small-Cap ETFSCHA2.17M0.01%21.7B USD0.03%$32.66+0.15%
Schwab Fundamental U.S. Small Company Index ETFFNDA2.01M0.02%8.72B USD0.25%$35.56+0.45%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHASchwab Fundamental U.S. Small Company Index ETFFNDAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
